GSE195557

TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

8 case / 8 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Objectives: TNF-induced activation of fibroblast-like synoviocytes (FLS) is a critical determinant for synovial inflammation and joint destruction in rheumatoid arthritis (RA). The detrimental role of TNF-receptor 1 (TNFR1) has thoroughly been characterized. The contributions of TNFR2, however, are largely unknown. This study was performed to delineate the role of TNFR2 in human FLS activation. Methods: TNFR2 expression in synovial tissue samples was determined by immunohistochemistry. Expression of TNFR2 was silenced using RNAi or CRISPR/Cas9 technologies. Global transcriptional changes were determined by RNA-seq. QPCR, ELISA and immunoblotting were used to validate RNA-seq results and to uncover pathways operating downstream of TNFR2 in FLS.  Results. TNFR2 expression was increased in RA when compared to OA synovial tissues. In particular, RA-FLS demonstrated higher levels of TNFR2 when compared to OA-FLS. TNFR2 expression in RA-FLS correlated with RA disease activity, synovial T- and B-cell infiltration. TNF and IL1 were identified as inflammatory mediators that upregulate TNFR2 in RA-FLS. Silencing of TNFR2 in RA-FLS markedly diminished the TNF-induced expression of inflammatory cytokines and chemokines, including CXCR3-binding chemokines and the B-cell activating factor TNFSF13B. Immunobiochemical analyses revealed that TNFR2-mediated expression of inflammatory mediators critically depends on STAT1. Conclusion: Our results define a critical role for TNFR2 in FLS-driven inflammation and unfold its participation in the unresolved course of synovial inflammation in RA.

Overall design

Examining the effect of TNFR2 knockdown on gene expression in TNF-stimulated fibroblast-like synoviocytes (FLS)

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
16 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. Rheumatology (Oxford, England), 2022
Available

Metadata Quality Components

Analysis Readiness

Ready after review
100% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

10/10 pts

No dataset warnings are present.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Standard analyst review

Proceed only after the analyst confirms grouping, exclusions, and source files.

By Siftome standards, no expert review was triggered.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Rheumatoid arthritis Disease context came from Normalization rules.
  • Likely case group Knockdown 8 samples
  • Likely control group Genetic control 8 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a treatment/control experiment. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Tissue. Comparison suitability: 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Rheumatoid arthritis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 35258553.
  • Publication context: TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation.. Rheumatology (Oxford, England), 2022. PMID 35258553. DOI 10.1093/rheumatology/keac124.

Cautions

  • Downgraded for tissue search because it is a treatment/control experiment.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

No dataset warnings

Normalized Fields

28 fields

Sample Group Preview

16 rows shown
Show Hide
Study totals: Case 8 | Control 8 | Unassigned 0 | Excluded 0 | Ambiguous 0 16 rows shown
Group Role Accession Title Source / characteristics Reason
Knockdown Case GSM5840490 St1_siTNFR2_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: TNF; Patient: St1 Genetic perturbation marker detected.
Knockdown Case GSM5840493 St2_siTNFR2_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: Control; Patient: St2 Genetic perturbation marker detected.
Knockdown Case GSM5840495 St2_siTNFR2_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: TNF; Patient: St2 Genetic perturbation marker detected.
Knockdown Case GSM5840498 St3_siTNFR2_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: Control; Patient: St3 Genetic perturbation marker detected.
Knockdown Case GSM5840499 St3_siTNFR2_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: TNF; Patient: St3 Genetic perturbation marker detected.
Knockdown Case GSM5840502 St4_siTNFR2_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: Control; Patient: St4 Genetic perturbation marker detected.
Knockdown Case GSM5840503 St4_siTNFR2_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: TNF; Patient: St4 Genetic perturbation marker detected.
Knockdown Case GSM5840504 St1_siTNFR2_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiTNFR2; Treatment: Control; Patient: St1 Genetic perturbation marker detected.
Genetic control Control GSM5840489 St1_sictrl_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: Control; Patient: St1 Genetic perturbation control marker detected.
Genetic control Control GSM5840491 St2_sictrl_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: Control; Patient: St2 Genetic perturbation control marker detected.
Genetic control Control GSM5840492 St2_sictrl_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: TNF; Patient: St2 Genetic perturbation control marker detected.
Genetic control Control GSM5840494 St1_sictrl_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: TNF; Patient: St1 Genetic perturbation control marker detected.
Genetic control Control GSM5840496 St3_sictrl_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: Control; Patient: St3 Genetic perturbation control marker detected.
Genetic control Control GSM5840497 St3_sictrl_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: TNF; Patient: St3 Genetic perturbation control marker detected.
Genetic control Control GSM5840500 St4_sictrl_ctrl Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: Control; Patient: St4 Genetic perturbation control marker detected.
Genetic control Control GSM5840501 St4_sictrl_TNF Fibrobst-like synoviocytes Tissue: Fibrobst-like synoviocytes; Disease: Rheumatoid Arthritis; Knockdown: SiControl; Treatment: TNF; Patient: St4 Genetic perturbation control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.